MY134672A - Stable crystal of 4-oxoquinoline compound - Google Patents

Stable crystal of 4-oxoquinoline compound

Info

Publication number
MY134672A
MY134672A MYPI20052258A MYPI20052258A MY134672A MY 134672 A MY134672 A MY 134672A MY PI20052258 A MYPI20052258 A MY PI20052258A MY PI20052258 A MYPI20052258 A MY PI20052258A MY 134672 A MY134672 A MY 134672A
Authority
MY
Malaysia
Prior art keywords
crystal
stable crystal
oxoquinoline compound
present
powder
Prior art date
Application number
MYPI20052258A
Other languages
English (en)
Inventor
Motohide Satoh
Takahisa Motomura
Takashi Matsuda
Kentaro Kondo
Koji Ando
Koji Matsuda
Shuji Miyake
Hideto Uehara
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY134672(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MY134672A publication Critical patent/MY134672A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
MYPI20052258A 2004-05-20 2005-05-18 Stable crystal of 4-oxoquinoline compound MY134672A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20

Publications (1)

Publication Number Publication Date
MY134672A true MY134672A (en) 2007-12-31

Family

ID=35079161

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20052258A MY134672A (en) 2004-05-20 2005-05-18 Stable crystal of 4-oxoquinoline compound

Country Status (33)

Country Link
US (7) US7635704B2 (en:Method)
EP (4) EP4299563A3 (en:Method)
JP (1) JP3754064B2 (en:Method)
KR (1) KR20080064909A (en:Method)
CN (1) CN1956961B (en:Method)
AR (2) AR049280A1 (en:Method)
AU (1) AU2005245296B2 (en:Method)
BE (1) BE2024C511I2 (en:Method)
BR (1) BRPI0510114B8 (en:Method)
CA (1) CA2566922C (en:Method)
CY (4) CY1113010T1 (en:Method)
DK (2) DK1636190T3 (en:Method)
ES (2) ES2960824T3 (en:Method)
FI (2) FI3281939T3 (en:Method)
FR (1) FR23C1040I1 (en:Method)
HR (2) HRP20120681T1 (en:Method)
HU (2) HUE064615T2 (en:Method)
IL (1) IL179250A0 (en:Method)
LT (2) LT3281939T (en:Method)
LU (1) LUC00334I2 (en:Method)
MX (1) MXPA06013405A (en:Method)
MY (1) MY134672A (en:Method)
NO (8) NO339223B1 (en:Method)
NZ (1) NZ551839A (en:Method)
PE (2) PE20060358A1 (en:Method)
PL (2) PL3281939T3 (en:Method)
PT (2) PT1636190E (en:Method)
RS (2) RS64845B1 (en:Method)
RU (1) RU2330845C1 (en:Method)
SI (2) SI1636190T1 (en:Method)
TW (1) TWI329015B (en:Method)
WO (1) WO2005113508A1 (en:Method)
ZA (1) ZA200610647B (en:Method)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
BRPI0306214B1 (pt) * 2002-11-20 2017-08-08 Japan Tobacco Inc. 4-oxoquinoline compound and use of this as a hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
JP4676536B2 (ja) * 2005-12-30 2011-04-27 ギリアド サイエンシズ， インコーポレイテッド Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
JP2009525261A (ja) * 2006-02-01 2009-07-09 日本たばこ産業株式会社 レトロウイルス感染症の治療のための、６−（３−クロロ−２−フルオロベンジル）−１−［（２ｓ）−１−ヒドロキシ−３−メチルブタン−２−イル］−７−メトキシ−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸またはその塩の使用
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
PL1992607T3 (pl) 2006-03-06 2015-05-29 Japan Tobacco Inc Sposób wytwarzania związku 4-oksochinolinowego
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
BRPI0714055B8 (pt) 2006-07-07 2021-05-25 Gilead Sciences Inc compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo
KR101555089B1 (ko) 2006-09-12 2015-09-22 길리애드 사이언시즈, 인코포레이티드 인테그라제 억제제의 제조를 위한 방법 및 중간체
HRP20161476T4 (hr) 2007-02-23 2024-07-05 Gilead Sciences, Inc. Modulatori farmakokinetičkih svojstava lijekova
KR20100028656A (ko) * 2007-06-29 2010-03-12 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
WO2009006199A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
PE20110994A1 (es) 2009-02-06 2012-01-24 Gilead Sciences Inc Comprimidos antivirales que comprenden elvitegravir, emtricitabina, disoproxil fumarato de tenofovir y un derivado de tiazol
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
RU2015103913A (ru) 2012-07-06 2016-08-27 Дженентек, Инк. N-замещенные бензамиды и способы их применение
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
PL2822954T3 (pl) 2012-12-21 2016-09-30 Policykliczne związki karbamoilopirydonu i ich farmaceutyczne zastosowanie
AU2014286993B2 (en) 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
NO2865735T3 (en:Method) 2013-07-12 2018-07-21
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (en:Method) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
PT3466490T (pt) 2015-04-02 2020-12-24 Gilead Sciences Inc Compostos de carbamoilpiridona policíclicos e sua utilização farmacêutica
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536B1 (en) * 2020-10-19 2025-06-25 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (en:Method) 1970-09-14 1981-02-16
JPS4826772A (en:Method) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
FI970195A7 (fi) 1994-07-18 1997-02-05 Ube Industries Trifluormetyylikinoliinikarboksyylihappojohdannainen
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
AU725629B2 (en) 1996-04-12 2000-10-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Acridone-derived compounds useful as antineoplastic and antiretroviral agents
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
WO2002036734A2 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
ES2274913T3 (es) 2000-10-12 2007-06-01 MERCK & CO., INC. Aza y poliaza-naftalenil carboxamidas utiles como inhibidores de vih integrada.
WO2002070486A1 (en) 2001-03-01 2002-09-12 Shionogi & Co., Ltd. Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
RU2206564C1 (ru) * 2002-03-07 2003-06-20 Общество с ограниченной ответственностью "Поливит" Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
BRPI0306214B1 (pt) 2002-11-20 2017-08-08 Japan Tobacco Inc. 4-oxoquinoline compound and use of this as a hiv integrase inhibitor
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP2332538A1 (en) 2004-05-21 2011-06-15 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents

Also Published As

Publication number Publication date
CN1956961B (zh) 2010-05-26
AU2005245296B2 (en) 2010-08-12
NO347902B1 (no) 2024-05-06
RS52375B (sr) 2012-12-31
FIC20240008I1 (fi) 2024-03-20
EP4299563A3 (en) 2024-02-28
HUS2400006I1 (hu) 2024-04-28
PL3281939T3 (pl) 2024-03-18
NO20240384A1 (no) 2007-02-07
CY1113010T1 (el) 2016-04-13
EP1636190A1 (en) 2006-03-22
EP3281939B1 (en) 2023-10-18
US20180029989A1 (en) 2018-02-01
US20190185433A1 (en) 2019-06-20
DK1636190T3 (da) 2012-09-24
FR23C1040I1 (fr) 2023-12-29
EP3281939A1 (en) 2018-02-14
FI3281939T3 (fi) 2023-10-23
RS64845B1 (sr) 2023-12-29
PE20120361A1 (es) 2012-05-03
JP2006001927A (ja) 2006-01-05
HRP20231588T3 (hr) 2024-03-15
AR096100A2 (es) 2015-12-09
PL1636190T3 (pl) 2012-10-31
SI1636190T1 (sl) 2012-09-28
CN1956961A (zh) 2007-05-02
CA2566922A1 (en) 2005-12-01
US20100204271A1 (en) 2010-08-12
AR049280A1 (es) 2006-07-12
TW200600097A (en) 2006-01-01
CY2015009I1 (el) 2024-09-20
US20150361044A1 (en) 2015-12-17
AU2005245296A1 (en) 2005-12-01
ES2388441T3 (es) 2012-10-15
HK1083341A1 (en) 2006-06-30
BRPI0510114B1 (pt) 2020-09-15
LT3281939T (lt) 2023-11-27
MXPA06013405A (es) 2007-03-01
CA2566922C (en) 2011-01-11
NO20220690A1 (no) 2007-02-07
NZ551839A (en) 2009-11-27
KR20080064909A (ko) 2008-07-09
BRPI0510114A (pt) 2007-09-25
LTC3281939I2 (en:Method) 2025-04-25
HUE064615T2 (hu) 2024-04-28
JP3754064B2 (ja) 2006-03-08
HRP20120681T1 (hr) 2012-09-30
BE2024C511I2 (en:Method) 2024-10-08
WO2005113508A1 (en) 2005-12-01
EP2514746A1 (en) 2012-10-24
NO20161297A1 (no) 2007-02-07
NO20190051A1 (no) 2007-02-07
EP1636190B1 (en) 2012-06-27
PT3281939T (pt) 2023-11-22
ES2960824T3 (es) 2024-03-06
PE20060358A1 (es) 2006-05-12
ZA200610647B (en) 2008-06-25
NO339223B1 (no) 2016-11-21
LUC00334I2 (en:Method) 2024-07-01
NO20230913A1 (no) 2007-02-07
EP4299563A2 (en) 2024-01-03
NO20200873A1 (no) 2007-02-07
CY1126560T1 (el) 2024-09-20
US20220235009A1 (en) 2022-07-28
TWI329015B (en) 2010-08-21
SI3281939T1 (sl) 2024-02-29
PT1636190E (pt) 2012-08-20
US20060030710A1 (en) 2006-02-09
CY2024008I1 (el) 2024-09-20
BRPI0510114B8 (pt) 2021-05-25
NO20065790L (no) 2007-02-07
IL179250A0 (en) 2007-03-08
CY2024008I2 (el) 2024-09-20
US20250091995A1 (en) 2025-03-20
DK3281939T3 (da) 2024-01-22
CY2015009I2 (el) 2024-09-20
NO2024034I1 (no) 2024-07-15
LTPA2024001I1 (en:Method) 2024-04-10
US7635704B2 (en) 2009-12-22
RU2330845C1 (ru) 2008-08-10
US8981103B2 (en) 2015-03-17

Similar Documents

Publication Publication Date Title
MY134672A (en) Stable crystal of 4-oxoquinoline compound
IL164597A0 (en) Substituted 3-amino-thienoÄ2,3-bÜpyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
WO2008071918A8 (en) Pyrido-pyrazine derivatives useful as herbicidal compounds
PL2170068T3 (pl) Sposób zwalczania owadów
WO2003016282A3 (en) Substituted 1h-dihydropyrazoles, their preparation and use
TW200716558A (en) Heteroaroyl-substituted serineamides
WO2008006043A3 (en) 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
TW200613280A (en) Heteroaroyl-substituted serineamides
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
WO2009121535A3 (en) Antiproliferative compounds and therapeutic uses thereof
PT2272824T (pt) Processo para a produção de 2,4¿-metilenodifenildiisocianato muito puro
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
TNSN07317A1 (en) 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof
EP1623971A4 (en) ASYMMETRIC SYNTHETIC CATALYST BASED ON BRONSTED CHIRAL ACID AND PROCESS FOR ASYMMETRIC SYNTHESIS THEREOF
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
MX2008015250A (es) Sales de acido clorhidrico de la 6-metoxi-8-[4-(1-(5-fluoro)-quino lin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina.
WO2007062308A3 (en) Homo- and heterocyclic compounds suitable as cetp inhibitors
PL1746097T3 (pl) Skondensowane heterocykle 1,4-dihydropirydynowe, sposób ich wytwarzania, zastosowanie i zawierające je kompozycje
UA96149C2 (en) Method for producing 4-oxoquinoline compound
WO2005077902A3 (en) Methods for the synthesis of pyridoxamine
AU2003230831A1 (en) ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-l, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN)
IL189879A0 (en) Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1h-[naphthyridin-2-one
TW200735776A (en) Use of pyraclostrobin as safener for triticonazole for controlling harmful fungi
WO2006055268A3 (en) Pyrimidothienoindazoles capable of inhibiting tyrosine kinases of the epidermal growth factor